Nanomedicine News

RSS

Arrowhead Research Invests $1 Million in Calando Pharmaceuticals

Arrowhead Research Corporation (NASDAQ: ARWR) (“the Company”) today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Cala...

From Arrowhead Pharmaceutical 19 Jan 2011

Korea-Based Wisepower Acquires Arrowhead's Subsidiary

Arrowhead Research Corporation today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based electronics company.

From Arrowhead Pharmaceutical 19 Jan 2011

Researchers Plan to Use Two-Photon Lithography to Grow Blood Vessels in Predetermined Patterns

Researchers from Rice University and Baylor College of Medicine (BCM) have broken one of the major roadblocks on the path to growing transplantable tissue in the lab: They've found a way to grow the blood vessels and capillaries needed to keep tissues alive.

14 Jan 2011

Scientists Focus on Feyman's Vision to Improve Nanoscience in Future

In the late 1950s, Richard Feynman famously imagined a science where researchers and engineers could achieve remarkable feats by manipulating matter and creating structures all the way down to the level of individual ato...

14 Jan 2011

Spaser Can Fuel Development of Future Nano-Sized Devices

Lasers have revolutionized the communications and medical industries. They focus light to zap tumors and send digital TV signals and telephone communications around the world. But the physical length of an ordinary l...

13 Jan 2011

CNSE Receives Federal Grants for Innovative Research in Nanotechnology

The College of Nanoscale Science and Engineering (“CNSE”) of the University at Albany today announced the receipt of nearly $5 million in federal funding awards to support innovative research and education in...

From College of Nanoscale Science and Engineering, University at Albany 12 Jan 2011

NanGenex Achieves First Milestone for Clinical Development of NanoActive Products

NanGenex Inc. has successfully completed the chemical validation of its latest GMP compliant pilot plant reactor.

From Tavanta Therapeutics 12 Jan 2011

Fluorescent Nanoparticles of Specific Sizes Created to Study Tumour Drug Absorption

Nanoparticles play a significant role in the development of future diagnostic and therapeutic techniques for tumors, for example as transporters for drugs or as contrast agents. Absorption and dispersion of nanoparticles in tumor tissue depend strongly on particle size. In order to systematically study this, scientists have now produced a set of fluorescent nanoparticles of various diameters between 10 and 150 nm.

From John Wiley and Sons - Scientific Publishers 11 Jan 2011

Celator Pharmaceuticals Extends Research Agreement with Cephalon

Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development.

11 Jan 2011

Tekmira Comments on Alnylam’s Recently Presented Clinical Data of ALN-VSP Candidate

Tekmira Pharmaceuticals Corporation a leading developer of RNA interference (RNAi) therapeutics, today provided the following comment on Alnylam Pharmaceuticals, Inc.'s recently presented data from a Phase 1 human clinical trial for ALN-VSP showing that analysis of human tissue samples demonstrated proof of RNAi in man.

11 Jan 2011